NCHR’s Public Comments on United States Preventive Services Task Force’s Draft Research Plan on Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents

We agree that it is very important to examine whether screening programs for depression, anxiety, and increased risk of suicide accurately identify children and adolescents with those conditions, as well as whether screening leads to improved health outcomes among children and adolescents. We agree that it is equally important to assess the potential harms of screening and treatment. There are, however, three points that we suggest should be re-examined in the draft research plan. 

Read More »

How to Cope with Coronavirus Anxiety

Anxiety can be scary, but it is possible to overcome it. If you are feeling like you are spinning out of control with anxiety reading the news about the coronavirus, this article can help.

Read More »

NCHR Testimony on Singulair and Neuropsychiatric Side Effects

September 27, 2019. Singulair has serious side effects and we need much better data to determine the likely benefit and risk of harm for patients. FDA has an important role to play in encouraging this research. In the meantime, patients, parents, and clinicians must be given clear information about the risks so that they can make an informed decision about whether to use montelukast (Singulair).

Read More »